BioAge Labs, Inc. (BIOA) Research
BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for metabolic illnesses. The company employs a distinctive technology platform alongside specialized human datasets to pinpoint potential drug targets by unraveling the molecular mechanisms underlying the aging process. Their current pipeline features azelaprag, an oral small molecule, which is undergoing Phase 1 clinical trials for obesity. Additionally, BioAge has commenced a Phase 2 clinical trial for azelaprag, investigating its efficacy in combination with tirzepatide for managing obesity specifically in older adults. Another asset under development is BGE-100, an oral, brain-penetrant small molecule designed to act as an NLRP3 antagonist, aiming to address conditions characterized by neuroinflammation. Established in 2015, BioAge Labs, Inc. operates from its headquarters in Richmond, California.
Market snapshot
- Symbol
- BIOA
- Price
- $20.77
- Day change
- +3.90%
- Market cap
- $782.0M
- P/E ratio
- -9.81x
- 52-week range
- 4.065-24
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $42.20
Recent news
- BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor.
Peer companies
Recent insider activity
- Pande Vijay Satyanand — A-Award (22000 shares) on 2026-06-10
- Hemrajani Rekha — A-Award (22000 shares) on 2026-06-10
- HEALY JAMES — A-Award (22000 shares) on 2026-06-10
- ENRIGHT PATRICK G — A-Award (22000 shares) on 2026-06-10
- Davidson Michael H. — A-Award (22000 shares) on 2026-06-10
Open BioAge Labs, Inc. (BIOA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.